Loading…
the sparker alert will let you know when a significant move starts with an audio alert, so You'll never miss an Opportunity.
Kodiak Sciences Inc Has Developed A New Technology Platform, The Antibody Biopolymer Conjugate (Abc) Platform, For Retinal Medicines. Its Investigational Medicine, Tarcocimab Tedromer (Zenkuda Or Tarcocimab), Is An Anti-Vegf Therapy Built On Kodiak'S Proprietary Abc Platform. Another Investigational Medicine, Ksi-501, Is An Anti-Interleukin 6, Or Il-6, Vegf-Trap Bispecific Therapy Built On The Abc Platform And Is Being Developed For High-Prevalence Retinal Vascular Diseases And Intended To Address The Unmet Needs Of Extended Durability And Targeting Disease Biology Beyond Vegf For Differentiated Efficacy. Its Third Investigational Medicine, Ksi-101, Is A High-Strength (100 Mg/Ml) Bispecific Protein Targeting Il-6 And Vegf.